氧化修饰低密度脂蛋白与动脉粥样硬化

动脉粥样硬化的发生发展与低密度脂蛋白受到氧化修饰有关。本文从以下四个方面对本室的工作进行了综述：（１）动脉粥样硬化机体受到脂质过氧化损伤;（２）Ｏｘ－ＬＤＬ对内皮细胞、平滑肌细胞和巨噬细胞的毒性效应;（３）Ｏｘ－ＬＤＬ和ＭＤＡ－ＬＤＬ的比较及与Ｏｘ－ＬＤＬ和ＭＤＡ－ＬＤＬ结合的清道夫受体的特征;（４）不同方法对ＬＤＬ氧化修饰的比较和以ＬＤＬ氧化修饰为模型对某些物质的抗氧化修饰研究。研究结果为动脉粥     

Ox-LDL和天然LDL诱导人动脉平滑肌细胞增殖中蛋白激酶A作用的初步研究

汪浩川等研究表明一定量Ｏｘ－ＬＤＬ能刺激培养人动脉ＳＭＣ细胞的增殖［１］,Ｄｅｊａｇｅｒ等采用交叉抑制实验证明兔ＳＭＣ细胞膜上有能结合Ｏｘ－ＬＤＬ的清道夫受体［２］,因此Ｏｘ－ＬＤＬ诱导培养人ＳＭＣ细胞增殖可能是Ｏｘ－ＬＤＬ作用于ＳＭＣ膜清道夫受体后...     

氧化HDL_2在大鼠肝窦状隙细胞内代谢

大鼠肝窦状隙细胞培养结果显示：氧化高密度脂蛋白２（ｏｘ－ＨＤＬ２）对异硫氰酸荧光素（ＦＩＴＣ）荧光标记ｏｘ－ＨＤＬ２的细胞结合有竞争抑制作用,而ＨＤＬ２则无。细胞内吞ＦＩＴＣ－ｏｘ－ＨＤＬ２的荧光强度（ＦＳ）和［３Ｈ］ＣＥ－ｏｘ－ＨＤＬ２（ｒ－ｏｘ－ＨＤＬ２）的放射强度分别是内吞ＦＩＴＣ－ＨＤＬ２的４５．５％和ｒＨＤＬ２的６１．４％。内吞ＦＳ主要存在于三氯醋酸（ＴＣＡ）沉淀部分,而放射强度主要存在于ＴＣＡ上清液部分。细胞释放的ＦＳ和放射活性分别是内吞量的６７．７％和１０．９％,且主要存在于ＴＣＡ可沉淀部分。结果提示：（１）大鼠肝窦状隙细胞可能存在着ｏｘ－ＨＤＬ受体,该受体不同于ＨＤＬ受体。（２）ｏｘ－ＨＤＬ２在细胞内代谢方式与ＨＤＬ２相似,均没有经历溶酶体分解途径。在细胞内载脂蛋白与胆固醇酯（ＣＥ）组分经历一个解离过程。细胞截留大部分ＣＥ后,将载脂蛋白（Ａｐｏ）与剩余ＣＥ重组成脂蛋白并以逆向胞饮方式释放到胞外。（３）氧化修饰减弱ＨＤＬ２逆向转运胆固醇能力     

IAA及KCN在黄瓜子叶离体叶绿体氧化还原作用过程中的相互作用

ＩＡＡ对于不同时期的叶绿体ＤＣＰＩＰ光还原均有促进效应。而对叶绿体的放氧效率的促进则随子叶叶岭的增长而下降至零。ＣＮ＾－（１０＾－３ｍｏｌ／Ｌ）存在时不同程度地抑制叶绿体的ＤＣＰＩＰ光还原和氧化放氧。而ＩＡＡ（１０＾－５,１０＾－４ｍｏｌ／Ｌ）则能消除ＣＮ＾－的抑制作用而仅表现ＬＡＡ原有的促进作用。同时,ＩＡＡ可以释放照光和不照光条件下ＫＣＮ对离体叶绿体分解外源Ｈ２Ｏ２的抑制。叶绿体光系统的光还原     

神经元缺氧复氧损伤时氧自由基的毒性作用及其机制＊

在原代分离培养Ｗｉｓｔａｒ乳鼠大脑皮质神经元上研究了缺氧复氧损伤（Ｈ／Ｒ）对神经细胞乳酸脱氢酶（ＬＤＨ）,漏出率,死亡率和脂质过氧化物含量的影响,并选用一氧化氮（ＮＯ）合酶抑制剂Ｌ－ＮＧ－硝基－精氨酸（Ｌ－ＮＮＡ）巯基供体Ｎ－乙酰半胱氨酸（ＮＡＣ）和超氧化物歧化酶（Ｃｕ,Ｚｎ－ＳＯＤ）三种自由基清除剂进行预保护等方法来探讨机制。结果表明 Ｈ／Ｒ损伤引起ＬＤＨ漏出率,细胞死亡率和脂过氧化物含量极显著     

神经元缺氧复氧损伤时氧自由基的毒性作用及其机制

在原代分离培养Ｗｉｓｔａｒ乳鼠大脑皮质神经元上研究了缺氧复氧损伤（Ｈ／Ｒ）对神经细胞乳酸脱氢酶（ＬＤＨ）,漏出率,死亡率和脂质过氧化物含量的影响,并选用一氧化氮（ＮＯ）合酶抑制剂Ｌ－ＮＧ－硝基－精氨酸（Ｌ－ＮＮＡ）巯基供体Ｎ－乙酰半胱氨酸（ＮＡＣ）和超氧化物歧化酶（Ｃｕ,Ｚｎ－ＳＯＤ）三种自由基清除剂进行预保护等方法来探讨机制。结果表明 Ｈ／Ｒ损伤引起ＬＤＨ漏出率,细胞死亡率和脂过氧化物含量极显著     

EGFR反义脱氧寡核苷酸及其硫代修饰片段抑制人肝癌细胞系BEL…

本文旨在研究针对ＥＧＦＲ ｍＲＮＡ的反义寡核苷酸片段对ＢＥＬ－７４０４细胞ＥＧＦＲ基因表达及其对细胞生长的影响。合成了互补于ＥＧＦＲ基因５’起始编码区的２１聚脱氧寡核苷酸（ＯＤＮｓ）。实验结果显示,３．２ｕｍｏｌ／Ｌ ＯＤＮｓ明显抑制ＢＥＬ－７４０４细胞生长,「３Ｈ」Ｔｄｒ掺入抑制试验显示其对细胞ＤＮＡ合成的抑制作用表现剂量依赖性;密度扫描分析显示ＯＤＮｓ处理６、２４ｈ后,肝癌细胞ＥＧＦＲ ｍＲＮ     

内皮素-1 mRNA反义寡核苷酸预防大鼠急性缺血性心律失常

本实验夹闭雄性ＳＤ大鼠冠状动脉左前降支（ＬＡＤ）造成急性心肌缺血,观察ＬＡＤ闭塞后１ｈ内缺血性心律失常的发生。在ＬＡＤ夹闭前２ｈ,静脉注射本室设计的人内皮素－１ｍＲＮＡ反义寡核苷酸（ＡＳ－ＯＤＮ）以阻断ＥＴ－１ｍＲＮＡ表达,观察ＡＳ－ＯＤＮ对血浆ＥＴ－１浓度和急性缺血性心律失常的影响。     

渗透胁迫下玉米幼叶延伸生长与生长部位质膜H~＋─ATPase的关系

－０．４ＭＰａ和－０．８ＭＰａＰＥＧ６０００对玉米幼叶延伸生长和生长部位Ｈ＋分泌有明显的抑制作用,但对生长部位ＰＭＨ＋－ＡＴＰａｓｅ则有不同程度的激活作用,正常水分条件下,Ｎａ３ＶＯ４和ＤＣＣＤ强烈抑制ＬＥＲ和Ｈ＋分泌,抑制程度ＤＣＣＤ＞Ｎａ３ＶＯ４,二者使膜透性增加的程度很相近。－０．４ＭＰａ　ＰＥＧ胁迫下,Ｎａ３ＶＯ４对ＬＥＲ和Ｈ＋分泌的抑制作用不明显,而ＤＣＣＤ仍显著抑制ＬＥＲ和Ｈ＋分泌;ＤＣＣＤ促进膜透性增加的程度远大于Ｎａ３ＶＯ４。     

脱氧雪腐镰刀菌烯醇对K~＋刺激的小麦根质膜ATP酶活性、K~＋吸收、外渗及再分配的影响

１０－８ｍｏｌ／Ｌ的ＤＯＮ毒素加入小麦根质膜制剂中可促进Ｋ＋刺激的ＡＴＰ酶活力,１０－６ｍｏｌ／Ｌ开始呈抑制效应,抑制程度随ＤＯＮ浓度加大而提高。根尖（５ｃｍ）离体根段于０．５ｍｍｏｌ／Ｌ的ＫＣｌ中,１０－８ｍｏｌ／Ｌ的ＤＯＮ能促进根段Ｋ＋吸收,１０－６ｍｏｌ／Ｌ以上浓度则Ｋ＋吸收呈抑制,１０－２ｍｏｌ／Ｌ浓度下根段的净吸收为负值,表明组织中Ｋ＋大量外渗。根段置蒸馏水中６ｈ,４ｍｍｏｌ／Ｌ的ＤＯＮ即导致振段Ｋ＋渗漏。用ＤＯＮ处理整株小麦根,浓度在０．２５ｍｍｏｌ／Ｌ以上可促进Ｋ＋从植株其它部位向根运输,而浓度在８ｍｍｏｌ／Ｌ时即抑制Ｋ＋向根富集,且根内Ｋ＋明显渗漏。     

Lipoprotein lipase genotypes for a common premature termination codon mutation detected by PCR-mediated site-directed mutagenesis and restriction digestion.

We have developed a procedure for the determination of a common mutation in exon 9 of the human lipoprotein lipase (LPL) gene. The mutation is due to a C-G transversion which creates a premature termination codon (Ser447-Ter) and results in a truncated LPL molecule lacking the C-terminal dipeptide SER-GLY. The mutation can be detected by polymerase chain reaction (PCR) amplification of exon 9 using a modified 3' amplimer that produces a 140 bp product containing a site for the restriction enzyme Hinf-1 in the presence of the mutation (G allele). The G allele was in strong linkage disequilibrium with a Hind-III restriction fragment length polymorphism (RFLP) allele in intron 8. Genotype determinations for the mutation can be performed by PCR amplification of genomic DNA, digestion with Hinf-1, and analysis of the products by polyacrylamide gel electrophoresis. The allelic frequency of the Ser447-Ter mutation in normal male Caucasian controls was 0.11. The frequency of the mutation was lower in a group of subjects with primary hypertriglyceridemia compared to normolipidemic controls.     

Lipoprotein lipase activity and common gene variants in severely hypertriglyceridemic patients with and without diabetes

OBJECTIVES: In severe type IV hypertriglyceridemia (triglyceride levels >10 g/l), it is yet unknown whether lipoprotein lipase (LPL) differs according to the presence or not of diabetes. METHODS: We compared LPL activity and the presence of four common variants in the LPL gene (Asp 9 Asn (exon 2), Gly 188 Glu (exon 5), Asn 291 Ser (exon 6) and Ser 447 Ter (exon 9)) in a group of 34 patients of whom 17 presented diabetes mellitus. RESULTS: Maximum triglyceride, cholesterol levels and distribution of apolipoprotein E phenotypes did not differ between the two subgroups. Mean post-heparin LPL activity was lower in non-diabetic compared to diabetic patients (9.74 vs. 12.98 micromol FFA/ml/h, p=0.033). Four patients were carrying a mutation in exon 9 (1 non-diabetic), 6 patients in exon 2 (4 non-diabetic) and 1 patient in the non-diabetic subgroup in exon 5. All mutations were at the heterozygous state. CONCLUSION: We found that LPL activity was lower in type IV hyperlipidemia in the absence of diabetes. Genetic defects in the LPL gene that could lead to this lower LPL tended to be more frequently observed in patients without diabetes. These data suggest that the pathomechanisms which contribute to severe type IV hyperlipidemia are different according to the presence or not of diabetes.     

Novel mutations of the lipoprotein lipase gene associated with hypertriglyceridemia in members of type 2 diabetic pedigrees

Increased plasma triglyceride and free fatty acid levels are frequently associated with type 2 diabetes mellitus (T2DM). To test the hypothesis that LPL gene mutations contribute to the hypertriglyceridemia observed in members of T2DM pedigrees, we screened the LPL gene in 53 hypertriglyceridemic members of 26 families. Four known and three novel mutations were identified. All three novel mutations, Lys312insC, Thr361insA, and double mutation Lys312insC + Asn291Ser, are clinically associated with hypertriglyceridemia. In vitro mutagenesis and expression studies confirm that these variants are associated with a significant reduction in LPL activity. The modeled structures displaying the Lys312insC and Thr361insA mutations showed loss of the activity-related C-terminal domain in the LPL protein. Another novel double mutation, Lys312insC + Asn291Ser, resulted in the loss of the catalytic ability of LPL attributable to the complete loss of the C-terminal domain and alteration in the heparin association site. Thus, these novel mutations of the LPL gene contribute to the hypertriglyceridemia observed in members of type 2 diabetic pedigrees.     

Two novel mutations in the lipoprotein lipase gene in a family with marked hypertriglyceridemia in heterozygous carriers. Potential interaction with the polymorphic marker D1S104 on chromosome 1q21-q23

Two novel mutations in the lipoprotein lipase (LPL) gene are described in an Austrian family: a splice site mutation in intron 1 (3 bp deletion of nucleotides -2 to -4) which results in skipping of exon 2, and a missense mutation in exon 5 which causes an asparagine for histidine substitution in codon 183 and complete loss of enzyme activity. A 5-year-old boy who exhibited all the clinical features of primary hyperchylomicronemia was a compound heterozygote for these two mutations. Nine other family members were investigated: seven were heterozygotes for the splice site mutation, one was a heterozygote for the missense mutation, and one had two wild-type alleles of the LPL gene. LPL activity in the post-heparin plasma of the heterozygotes was reduced to 49;-79% of the mean observed in normal individuals. Two of the heterozygotes had extremely high plasma triglyceride levels; in three of the other heterozygotes the plasma triglycerides were also elevated. As plasma triglycerides in carriers of one defective LPL allele can be normal or elevated, the heterozygotes of this family have been studied for a possible additional cause of the expression of hypertriglyceridemia in these subjects. Body mass index, insulin resistance, mutations in other candidate genes (Asn291Ser and Asp9Asn in the LPL gene, apoE isoforms, polymorphisms in the apoA-II gene and in the apoAI-CIII-AIV gene cluster, and in the IRS-1 gene) could be ruled out as possible factors contributing to the expression of hypertriglyceridemia in this family. A linkage analysis using the allelic marker D1S104 on chromosome 1q21;-q23 suggested that a gene in this region could play a role in the expression of hypertriglyceridemia in the heterozygous carriers of this family, but the evidence was not sufficiently strong to prove this assumption. Nevertheless, this polymorphic marker seems to be a good candidate for further studies.     

Gene polymorphisms in the Quebec population: a risk to develop hypertriglyceridemia

In Eastern Québec, two major lipoprotein lipase (LPL) gene mutations, P207L and G188E, lead to complete LPL deficiency in homozygote subjects and contribute to elevated predisposition to hypertriglyceridemia in heterozygotes. First, we determined the allele frequencies of LPL (D9N, G188E, P207L, D250N, N291S, and S447X), APOE (C112R and C158R), PPARalpha (L162V), and PPARgamma2 (P12A) single nucleotide polymorphisms (SNPs) in a random-based cohort of the metropolitan Québec city area. Second, we compared the LPL X447 allele frequencies observed in the random cohort and in a cohort of LPL P207L deficient patients. In the random cohort, the LPL N9 rare allele exhibited a higher prevalence than previously expected (p=0.0001). The LPL X447 allele frequency was lower in the patient cohort (Freq: 4.4%) than in the random cohort (Freq: 11.2%) (p=0.0001). These results reveal the importance of genetic screening for LPL gene mutations D9N and S447X in a population at risk to develop hypertriglyceridemia.     

A missense mutation (Asp250----Asn) in exon 6 of the human lipoprotein lipase gene causes chylomicronemia in patients of different ancestries.

We have previously reported two common lipoprotein lipase (LPL) gene mutations underlying LPL deficiency in the majority of 37 French Canadians (Monsalve et al., 1990. J. Clin. Invest. 86: 728-734; Ma et al., 1991. N. Engl. J. Med. 324: 1761-1766). By examining the 10 coding exons of the LPL gene in another French Canadian patient, we have identified a third missense mutation that is found in two of the three remaining patients for whom mutations are undefined. This is a G to A transition in exon 6 that results in a substitution of asparagine for aspartic acid at residue 250. Using in vitro site-directed mutagenesis, we have confirmed that this mutation causes a catalytically defective LPL protein. In addition, the Asp250----Asn mutation was also found on the same haplotype in an LPL-deficient patient of Dutch ancestry, suggesting a common origin. This mutation alters a TaqI restriction site in exon 6 and will allow for rapid screening in patients with LPL deficiency.     

Sequence analysis of exon 8 of MAO-A gene in alcoholics with antisocial personality and normal controls

Brunner et al. (1993, Science 262, 578-580) reported a family in which several males were affected by a syndrome of borderline mental retardation and abnormal behavior. Sequencing of exon 8 of the MAO-A gene revealed a mutation that results in a termination codon and was associated with the syndrome in the family. To determine the possible role of any mutation in exon 8 of the MAO-A gene in susceptibility to alcoholism associated with antisocial personality (ASP), we sequenced genomic DNA from 50 alcoholics and 50 normal controls. We detected only the point mutation at the position 941 (T --> G). Additional samples of alcoholics and normal controls were also screened for this mutation and the mutation in exon 14 by PCR assays. Comparison of alcoholics with ASP to normal controls for both mutation frequencies in exons 8 and 14 was positive. However, the haplotype frequency differences in the above groups were borderline significant. The most common haplotype between these mutations and a (CA)n repeat marker in the gene was F1E,C6. The frequency differences between alcoholics with ASP and normal controls for this haplotype were significant (P = 0.033). In TDT analysis, comparison of the overall haplotypes, transmitted to nontransmitted, was borderline significant. These data indicate that mutations in the MAO-A gene may play a role in the development of alcoholism associated with ASP.     

Molecular basis of familial chylomicronemia: mutations in the lipoprotein lipase and apolipoprotein C-II genes.

The molecular basis of familial chylomicronemia (type I hyperlipoproteinemia), a rare autosomal recessive trait, was investigated in six unrelated individuals (five of Spanish descent and one of Northern European extraction). DNA amplification by polymerase chain reaction (PCR) followed by single strand conformation polymorphism (SSCP) analysis allowed rapid identification of the underlying mutations. Six different mutant alleles (three of which are previously undescribed) of the gene encoding lipoprotein lipase (LPL) were discovered in the five LPL-deficient patients. These included an 11 bp deletion in exon 2, and five missense mutations: Trp 86 Arg (exon 3), His 136 Arg (exon 4), Gly 188 Glu (exon 5), Ile 194 Thr (exon 5), and Ile 205 Ser (exon 5). The Trp 86 Arg mutation is the only known missense mutation in exon 3. The other missense mutations lie in the highly conserved "central homology region" in close proximity with the catalytic site of LPL. These and other previously reported missense mutations provide insight into structure/function relationships in the lipase family. The missense mutations point to the important role of particular highly conserved helices and beta-strands in proper folding of the LPL molecule, and of certain connecting loops in the catalytic process. A nonsense mutation (Arg 19 Term) in the gene encoding apolipoprotein C-II (apoC-II), the cofactor of LPL, was found to underlie chylomicronemia in the sixth patient who had normal LPL but was apoC-II-deficient.     

The mitochondrial tRNA(Thr) A15951G mutation may influence the phenotypic expression of the LHON-associated ND4 G11778A mutation in a Chinese family

We report here the characterization of a three-generation Han Chinese family with Leber's hereditary optic neuropathy (LHON). This Chinese family exhibited high penetrance and expressivity of visual impairment. The average age-of-onset was 19 years in this family. All male and 33% female matrilineal relatives in this Chinese family developed visual loss with a wide range of severity, ranging from blindness to normal vision. Sequence analysis of the complete mitochondrial DNA in this pedigree revealed the presence of the ND4 G11778A mutation and 40 other variants, belonging to the Asian haplogroup D4. The G11778A mutation is present at homoplasmy in matrilineal relatives of this Chinese family. Of other variants, the homoplasmic A15951G mutation is of special interest as it is located adjacent to 3' end, at conventional position 71 of tRNA(Thr). The adenine (A71) at this position of tRNA(Thr), highly conserved from bacteria to human mitochondria, has been implicated to be important for tRNA identity and pre-tRNA processing. In fact, the significant reduction of the steady-state levels in tRNA(Thr) was observed in cells carrying both the A15951G and G11778A mutations but not cells carrying only G11778A mutation. Thus, the A15951G mutation most probably leads to a failure in mitochondrial tRNA metabolism, worsening the mitochondrial dysfunction associated with the primary G11778A mutation. These imply that the tRNA(Thr) A15951G mutation may have a potential modifier role in increasing the penetrance and expressivity of the primary LHON-associated G11778A mutation in this Chinese family.     

中国人群脂蛋白脂肪酶基因突变与高脂血症的相关性研究

为进行脂蛋白脂肪酶基因突变与中国人群高脂血症的相关性研究,采用单链构象多态性分析结合DNA序列测定的方法,对386例(其中108例高脂血症患者,278例正常对照)中国人群进行突变筛查。结果发现1个新的沉默突变L103L,1个错义突变P207L,3个剪接突变Int3/3′-ass/C(-6)→T和普遍存在的S447X多态性,其中发生在高脂血症组的P207L杂合子为亚洲首报,并对先证者的家系进行了研究,认为P207L是家族性高脂血症的病因之一,而在正常对照组中也有发现的Int3/3′-ass/C(-6)→T,对以往研究认为其是高脂血症易患因素的观点提出了相反的报告,对于普遍认为有益的多态性位点S447X,进一步研究认为其对于正常人群,特别是健康男性的保护作用更强。结论:脂蛋白脂肪酶基因变异与高脂血症的相关性十分复杂多样,大规模的人群筛查具有重要意义。